ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near Warszawa, Mazowieckie, POL:

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Other: Ofatumumab placebo
Drug: Siponimod

Phase 3

Novartis
Novartis

Warsaw, Poland and 73 other locations

This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily o...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis (RRMS)
Drug: IMU-838 (10 mg/day)
Drug: Placebo

Phase 2

Immunic Therapeutics

Warszawa, Poland and 37 other locations

the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple...

Enrolling
Progressive Multiple Sclerosis
Drug: Placebo
Drug: Masitinib (4.5)

Phase 3

AB Science
AB Science

Warsaw, Poland and 36 other locations

Locations recently updated

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

Phase 3

Roche
Roche

Warszawa, Poland and 161 other locations

(IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with m ...

Enrolling
Multiple Sclerosis
Drug: RO7121932 - MAD
Drug: RO7121932 SC - SAD

Phase 1

Roche
Roche

Warszawa, Poland and 23 other locations

effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (Qo...

Active, not recruiting
Multiple Sclerosis
Drug: Beta-Interferon
Drug: Methylprednisolone

Phase 3

Genzyme
Genzyme

Warszawa, Poland and 20 other locations

with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and \< 18 years over a dura...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Other: Ocrelizumab Placebo
Drug: Ocrelizumab

Phase 3

Roche
Roche

Warszawa, Poland and 120 other locations

The primary objective of Part 2 is to evaluate the long-term safety of BG00012 in subjects who completed Week 96 in Part 1 of Study 109MS306...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis
Drug: dimethyl fumarate
Drug: Interferon β-1a

Phase 3

Biogen
Biogen

Warsaw, Poland and 61 other locations

The primary objectives are to investigate the safety and tolerability of BIIB091 monotherapy in participants with relapsing multiple sclerosis...

Enrolling
Relapsing Forms of Multiple Sclerosis
Drug: BIIB091
Drug: DRF

Phase 2

Biogen
Biogen

Warszawa, Poland and 75 other locations

and adolescents ages ≥ 10 to ≤ 18 years with relapsing-remitting multiple sclerosis (RRMS). The data from this study will serve to ...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

Phase 2

Roche
Roche

Warszawa, Poland and 11 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems